HeartSciences COO and Longtime Board Member Passes Away

The latest announcement is out from Heart Test Laboratories, Inc. ( (HSCS) ).

On April 1, 2026, HeartSciences Inc. announced that Chief Operating Officer, Corporate Secretary and longtime board member Mark Hilz passed away at age 67 after a period of illness, following his service on the board since 2013 and in executive roles since March 2022. The company stated it does not plan to replace the COO role and does not expect his death to alter its operations or the planned commercialization of its MyoVista Insights platform, including the MyoVista wavECG device, which was submitted to the U.S. Food and Drug Administration in December 2025 for 510(k) clearance.

The most recent analyst rating on (HSCS) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Heart Test Laboratories, Inc. stock, see the HSCS Stock Forecast page.

Spark’s Take on HSCS Stock

According to Spark, TipRanks’ AI Analyst, HSCS is a Underperform.

The score is driven primarily by very weak financial performance (minimal revenue, massive losses, and heavy cash burn) and a stressed capital structure with high leverage. Technical indicators add further pressure with the stock trading below major moving averages and negative MACD, while valuation provides little support due to a negative P/E and no dividend yield.

To see Spark’s full report on HSCS stock, click here.

More about Heart Test Laboratories, Inc.

HeartSciences Inc. operates in the medical technology sector, focusing on cardiovascular diagnostics through its MyoVista Insights software platform and MyoVista wavECG device. The company targets improvements in heart disease detection using advanced ECG-based analysis and is progressing its flagship device through the U.S. regulatory clearance process.

Average Trading Volume: 20,642

Technical Sentiment Signal: Sell

Current Market Cap: $7.32M

For a thorough assessment of HSCS stock, go to TipRanks’ Stock Analysis page.